Patent Forge Spółka z Ograniczoną Odpowiedzialnością (KRS 0000852385, NIP 6751732209) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. PATENT FORGE operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since July 29, 2020.
Historical suspension of activities
Suspension: April 1, 2021 - resumed: May 28, 2025
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Patent Forge
Identity
- Name
- Patent Forge Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- July 29, 2020
- Registry status as of
- November 21, 2025
- Latest entry
- May 28, 2025
- Founding act
- 24.07.2020
Articles of association history (1)
- July 24, 2020: 24.07.2020
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- GRZEGÓRZECKA, 67D, 26, 31-559, KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- KRAKÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Operational status - Patent Forge
Founded
July 29, 2020
5 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
80 shares total
Shareholders
1
shareholder
Board
N/A
Filed years
N/A
Registry entries
11
latest: May 28, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Patent Forge.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
